Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389428 · ClinicalTrials.gov registry record · Phase 1
Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
A Phase 1 study of Hematologic Neoplasms, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT00389428 is a Phase 1 study of Hematologic Neoplasms that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 48 participants, below the 1,024-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT00389428, a Phase 1 study of Hematologic Neoplasms, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of this study is to determine the recommended dose of CPX-351 for use in a phase 2 efficacy study in patients with leukemia. Secondarily, the study will assess the safety, serious adverse effects and how the body handles CPX-351. Preliminary evidence of antitumor activity will also be determined.
Conditions Studied
Interventions
- DRUG CPX-351 (Cytarabine:Daunorubicin) Liposome Injection
Study Locations (4)
New York
- North Shore University Hospital - Manhasset
- New York Presbyterian Hospital Weill Medical College of Cornell University - New York
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Florida
- H. Lee Moffit Cancer Center & Research Institute at the University of S. Florida - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389428
The ClinicalTrials.gov registry entry for NCT00389428 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,024-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (95% lower). The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which CPX-351 (Cytarabine:Daunorubicin) Liposome Injection is the first listed.
NCT00389428 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT00389428 about?
NCT00389428 is a clinical study titled "Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.". The primary objective of this study is to determine the recommended dose of CPX-351 for use in a phase 2 efficacy study in patients with leukemia. Secondarily, the study will assess the safety, serious adverse effects and how the body handles CPX-351. Preliminary evidence of antitumor activity will ...
What is the current status of trial NCT00389428?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2006-09. Estimated completion is 2009-12.
What conditions does trial NCT00389428 study?
This clinical trial studies the following conditions: Hematologic Neoplasms.
What interventions are being tested in trial NCT00389428?
The interventions under investigation include: CPX-351 (Cytarabine:Daunorubicin) Liposome Injection (DRUG).
Who is sponsoring clinical trial NCT00389428?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00389428 being conducted?
This trial has 4 study locations across District of Columbia, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
RECRUITING · Phase 1
-
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
RECRUITING · Phase 1
-
Optimizing PTCy Dose and Timing
ACTIVE NOT RECRUITING · Phase 1
-
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
ACTIVE NOT RECRUITING · Phase 1
-
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.